Sign in

CIK 0001664710 · Non-accelerated filer<br>Smaller reporting company

Keros Therapeutics, Inc.

Sign in to watch
Ticker
KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
operating
EIN
811173868
Phone
617-314-6297
Business address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
  1. 4 Open-market buy Director bought 1,000 shares at $11.70 ($11,700)
  2. 4 Option exercise CHIEF EXECUTIVE OFFICER acquired 55,000 shares (option exercise)
  3. 4/A Derivatives Options or other derivatives
  4. 4 Grant or award Director acquired 13,215 shares (grant or award)
  5. 3 Insider Initial Statement of Ownership
  6. 4 Open-market buy Director bought 2,000 shares at $11.21 ($22,420)
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Open-market sale CHIEF EXECUTIVE OFFICER sold 7,015 shares at $16.17 ($113,433)
  12. 4 Open-market sale Chief Science Officer sold 3,873 shares at $16.35 ($63,324)
  13. 4 Open-market sale SVP, General Counsel sold 4,745 shares at $16.35 ($77,581)
  14. 4 Open-market sale CHIEF FINANCIAL OFFICER sold 4,739 shares at $16.35 ($77,483)
  15. 4 Derivatives Options or other derivatives
  16. 4 Returned to the company Director returned 214,522 shares (to the company)
  17. 4 Returned to the company Director returned 214,522 shares (to the company)
  18. 4 Returned to the company Director returned 322,021 shares (to the company)
  19. 4 Open-market sale 10% owner sold 4,787,331 shares at $17.75 ($84,975,125)
  20. 4 Open-market sale 10% owner sold 5,389,264 shares at $17.75 ($95,659,436)

Page 2 of 11 · 206 filings